Neurocrine’s Crenessity Shows Lasting Hormonal Control in CAH Study

Neurocrine Biosciences has shared new one-year data from its Phase III CAHtalyst Adult study, demonstrating that Crenessity (crinecerfont) helps adults with classic congenital adrenal hyperplasia (CAH) achieve lower, physiologic glucocorticoid (GC) doses while maintaining balanced hormone levels. The trial enrolled 182 adults aged 18–58 and included a 24-week double-blind, placebo-controlled phase followed by a 24-week open-label phase.

Results showed sustained improvements in adrenocorticotropic hormone (ACTH), androstenedione, and 17-hydroxyprogesterone levels, along with reduced GC dosing. Participants also showed gains in insulin resistance and hirsutism symptoms, especially among females.

Presented at ENDO 2025, the findings confirm Crenessity’s role in rebalancing adrenal hormones while minimizing reliance on high-dose steroids. The therapy was generally well tolerated, with fatigue and headache as the most common side effects.

Crenessity is a CRF1 receptor antagonist, and Neurocrine previously reported positive results in pediatric CAH trials in 2023.

15-07-2025